目的 :探讨PEI作为免疫佐剂对G250抗原肽基因PVAX1/C-G250肽-C免疫保护效果的增强作用及联合应用CAIX蛋白疫苗进行PRIME—BOOST免疫程序免疫增强效果。方法:用Eco R I、Xho I和Eco R I、Sal I分别双酶切PVAX1及既往构建的p ET28a(+)/C-G...目的 :探讨PEI作为免疫佐剂对G250抗原肽基因PVAX1/C-G250肽-C免疫保护效果的增强作用及联合应用CAIX蛋白疫苗进行PRIME—BOOST免疫程序免疫增强效果。方法:用Eco R I、Xho I和Eco R I、Sal I分别双酶切PVAX1及既往构建的p ET28a(+)/C-G250肽-C质粒。利用DNA重组技术构建重组质粒PVAX1/C-G250肽-C,酶切分析鉴定。大量提取质粒并分光光度计测质粒含量。将32只雌性昆明小鼠随机分为(A)裸DNA组,(B)DNA-PEI复合物组,(C)DNA-PEI+蛋白疫苗组,(D)空白对照组。按0,10,20,30天程序经股四头肌注射免疫。C组在第20天及第30天进行蛋白冲击。初次免疫前和第40天鼠尾取血,ELISA法检测抗体滴度。流式细胞术测淋巴细胞亚群CD4+和CD8+。结果:酶切及基因测序鉴定证实G250抗原肽c DNA正确插入PVAX1/C-G250肽-C真核表达的重组质粒中。昆明小鼠经4次免疫后,3个实验组都产生了特异性的体液和细胞免疫反应,B组的抗体滴度1:1.28×104及CD4+、CD8+达26.12%和12.60%,明显高于A组的1:3.2×103和CD4+,CD8+占到19.32%和10.74%。而蛋白冲击组的1:5.12×104和CD4+,CD8+占到41.96%和15.14%,明显高于B组(P>0.05)。结论:成功构建重组质粒PVAX1/C-G250肽-C。该DNA疫苗与PEI和G250蛋白疫苗联合使用后产生极强的免疫原性,诱导产生了高滴度、高特异性抗体及细胞免疫反应。证实G250DNA疫苗联合PEI使用并进行蛋白疫苗冲击的免疫策略可产生强大的免疫保护作用。为恶性肿瘤的术后辅助治疗提供新的思路和方法。展开更多
This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of re- combinant DNA （pCCMp24） and recombinant attenuated vaccinia virus Tian Tan （rddVTT_ccMpe4）. ...This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of re- combinant DNA （pCCMp24） and recombinant attenuated vaccinia virus Tian Tan （rddVTT_ccMpe4）. Intramuscular immuniza- tion was performed on days 0 （prime） and 21 （boost）. The immunogenicity of the vaccine schedules was determined by meas- uring human immunodeficiency virus （HIV）-specific binding antibody levels and cytokine （interleukin-2 and interleukin-4） concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4~/CD8＋cell ratio, and monitoring interferon-gamma levels at different times post-immunization. The results showed that pCCMp24, rddVTT.ccMp24 and their prime-boost immunization induced humoral and cellular immune responses. The pCCMp24/ rddVTT.ccMp24 immunization strategy increased CD8＋ T cells and induced more IFN-7-secreting cells compared with sin- gle-shot rDNA. The prime-boost immunization strategy also induced the generation of cellular immunological memory to HIV epitope peptides. These results demonstrated that prime-boost immunization with rDNA and rddVTT_ccMp24 had a tendency to induce greater cellular immune response than single-shot vaccinations, especially IFN-7 response, providing a basis for further studies.展开更多
CD4^(+)T cells are essential for sustaining CD8^(+)T cell responses during a chronic infection.The adoptive transfer of virus-specific CD4^(+)T cells has been shown to efficiently rescue exhausted CD8^(+)T cells.Howev...CD4^(+)T cells are essential for sustaining CD8^(+)T cell responses during a chronic infection.The adoptive transfer of virus-specific CD4^(+)T cells has been shown to efficiently rescue exhausted CD8^(+)T cells.However,the question of whether endogenous virus-specific CD4^(+)T cell responses can be enhanced by certain vaccination strategies and subsequently reinvigorate exhausted CD8^(+)T cells remains unexplored.In this study,we developed a CD4^(+)T cell epitope-based heterologous prime-boost immunization strategy and examined the efficacy of this strategy using a mouse model of chronic lymphocytic choriomeningitis virus(LCMV)infection.We primed chronically LCMV-infected mice with a Listeria monocytogenes vector that expressed the LCMV glycoprotein-specific I-Ab-restricted CD4^(+)T cell epitope GP61–80(LM-GP61)and subsequently boosted the primed mice with an influenza virus A(PR8 strain)vector that expressed the same CD4^(+)T cell epitope(IAV-GP61).This heterologous prime-boost vaccination strategy elicited strong anti-viral CD4^(+)T cell responses,which further improved both the quantity and quality of the virusspecific CD8^(+)T cells and led to better control of the viral loads.The combination of this strategy and the blockade of the programmed cell death-1(PD-1)inhibitory pathway further enhanced the anti-viral CD8^(+)T cell responses and viral clearance.Thus,a heterologous prime-boost immunization that selectively induces virus-specific CD4^(+)T cell responses in conjunction with blockade of the inhibitory pathway may represent a promising therapeutic approach to treating patients with chronic viral infections.展开更多
文摘目的 :探讨PEI作为免疫佐剂对G250抗原肽基因PVAX1/C-G250肽-C免疫保护效果的增强作用及联合应用CAIX蛋白疫苗进行PRIME—BOOST免疫程序免疫增强效果。方法:用Eco R I、Xho I和Eco R I、Sal I分别双酶切PVAX1及既往构建的p ET28a(+)/C-G250肽-C质粒。利用DNA重组技术构建重组质粒PVAX1/C-G250肽-C,酶切分析鉴定。大量提取质粒并分光光度计测质粒含量。将32只雌性昆明小鼠随机分为(A)裸DNA组,(B)DNA-PEI复合物组,(C)DNA-PEI+蛋白疫苗组,(D)空白对照组。按0,10,20,30天程序经股四头肌注射免疫。C组在第20天及第30天进行蛋白冲击。初次免疫前和第40天鼠尾取血,ELISA法检测抗体滴度。流式细胞术测淋巴细胞亚群CD4+和CD8+。结果:酶切及基因测序鉴定证实G250抗原肽c DNA正确插入PVAX1/C-G250肽-C真核表达的重组质粒中。昆明小鼠经4次免疫后,3个实验组都产生了特异性的体液和细胞免疫反应,B组的抗体滴度1:1.28×104及CD4+、CD8+达26.12%和12.60%,明显高于A组的1:3.2×103和CD4+,CD8+占到19.32%和10.74%。而蛋白冲击组的1:5.12×104和CD4+,CD8+占到41.96%和15.14%,明显高于B组(P>0.05)。结论:成功构建重组质粒PVAX1/C-G250肽-C。该DNA疫苗与PEI和G250蛋白疫苗联合使用后产生极强的免疫原性,诱导产生了高滴度、高特异性抗体及细胞免疫反应。证实G250DNA疫苗联合PEI使用并进行蛋白疫苗冲击的免疫策略可产生强大的免疫保护作用。为恶性肿瘤的术后辅助治疗提供新的思路和方法。
基金supported by the National Natural Science Foundation of China (81001342)the National Basic Research Program of China (2011CB512110)the National Mega Project on Major Infectious Diseases Prevention (2012ZX10001005-006)
文摘This study assessed and compared the immunogenicity of various immunization strategies in mice using combinations of re- combinant DNA （pCCMp24） and recombinant attenuated vaccinia virus Tian Tan （rddVTT_ccMpe4）. Intramuscular immuniza- tion was performed on days 0 （prime） and 21 （boost）. The immunogenicity of the vaccine schedules was determined by meas- uring human immunodeficiency virus （HIV）-specific binding antibody levels and cytokine （interleukin-2 and interleukin-4） concentrations in peripheral blood, analyzing lymphocyte proliferation capacity against HIV epitopes and CD4~/CD8＋cell ratio, and monitoring interferon-gamma levels at different times post-immunization. The results showed that pCCMp24, rddVTT.ccMp24 and their prime-boost immunization induced humoral and cellular immune responses. The pCCMp24/ rddVTT.ccMp24 immunization strategy increased CD8＋ T cells and induced more IFN-7-secreting cells compared with sin- gle-shot rDNA. The prime-boost immunization strategy also induced the generation of cellular immunological memory to HIV epitope peptides. These results demonstrated that prime-boost immunization with rDNA and rddVTT_ccMp24 had a tendency to induce greater cellular immune response than single-shot vaccinations, especially IFN-7 response, providing a basis for further studies.
基金The work was supported by National Basic Research Program of China(973 program,2013CB531500,to LY)the National Natural Science Foundation of China(81471624 to LY).
文摘CD4^(+)T cells are essential for sustaining CD8^(+)T cell responses during a chronic infection.The adoptive transfer of virus-specific CD4^(+)T cells has been shown to efficiently rescue exhausted CD8^(+)T cells.However,the question of whether endogenous virus-specific CD4^(+)T cell responses can be enhanced by certain vaccination strategies and subsequently reinvigorate exhausted CD8^(+)T cells remains unexplored.In this study,we developed a CD4^(+)T cell epitope-based heterologous prime-boost immunization strategy and examined the efficacy of this strategy using a mouse model of chronic lymphocytic choriomeningitis virus(LCMV)infection.We primed chronically LCMV-infected mice with a Listeria monocytogenes vector that expressed the LCMV glycoprotein-specific I-Ab-restricted CD4^(+)T cell epitope GP61–80(LM-GP61)and subsequently boosted the primed mice with an influenza virus A(PR8 strain)vector that expressed the same CD4^(+)T cell epitope(IAV-GP61).This heterologous prime-boost vaccination strategy elicited strong anti-viral CD4^(+)T cell responses,which further improved both the quantity and quality of the virusspecific CD8^(+)T cells and led to better control of the viral loads.The combination of this strategy and the blockade of the programmed cell death-1(PD-1)inhibitory pathway further enhanced the anti-viral CD8^(+)T cell responses and viral clearance.Thus,a heterologous prime-boost immunization that selectively induces virus-specific CD4^(+)T cell responses in conjunction with blockade of the inhibitory pathway may represent a promising therapeutic approach to treating patients with chronic viral infections.
